Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: CBCR for Acute Myocardial Infarction (AMI)
The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy lifestyle behaviors, better manage cardiovascular risk factors, and improve overall health outcomes. Cardiac rehabilitation is an evidence-based outpatient program designed to help people recover from heart-related conditions through supervised exercise, education, counseling, and support for healthy lifestyle changes.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are CBCR, or BRIDGE mHealth intervention. The registry lists allocation as randomized. The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy lifestyle behaviors, better manage cardiovascular risk factors, and improve overall health outcomes.
They plan to enroll about 30 people at Chicago. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
Official title (unrewritten)
BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation as a Model for Chronic Disease Management
Interventions: CBCR, BRIDGE mHealth intervention
Primary outcome (registry wording): Functional capacity as measured by peak metabolic equivalents (METs).
Who it is for (from inclusion criteria)
Ages 18 Years to any
Adults aged 18 years or older
Enrolled in or referred to Phase II Center-based Cardiac Rehabilitation Program
Have a qualifying cardiovascular diagnosis or event that meets standard eligibility for Phase II Center-based Cardiac Rehabilitation, such as:
Acute myocardial infarction
Percutaneous coronary intervention
Coronary artery bypass graft surgery
Chronic heart failure with reduced ejection fraction
Who the registry excludes
Not enrolled in or not planning to participate in Phase II Center-based Cardiac Rehabilitation Program
Presence of a medical, cognitive, psychiatric, or physical condition that, in the opinion of the investigators or CR team, would preclude safe participation in the study or adherence to study procedures
Terminal illness or other serious medical condition that in the judgement of the treating clinician or investigator would likely preclude completion of the study follow-up period.
Current hospice enrollment or residence in a long-term care facility that would preclude participation in the intervention or completion of study follow-up procedures
Currently participating in another behavioral or digital health intervention trial that could confound study outcomes
Inability or unwillingness to use the required mobile devices, applications, or monitoring equipment, if applicable
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers.
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to measure the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07741396?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07741396?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.